Pancreatic Cancer Clinical Trials in Dallas

Showing 41-60 of 102 trials

Tempus Priority Study: A Pan-tumor Observational Study

NCT05179824

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Breast CancerProstate CancerBladder Cancer+24 more

Tempus AI1,000 participantsStarted Oct 2020

Dallas, Texas, United States • Houston, Texas, United States

TERMINATEDPhase 2< 1 mile

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

Locally Advanced Solid TumorMetastatic Solid TumorPancreatic Cancer+14 more

Elevation Oncology54 participantsStarted Sep 2020

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Fountain Valley, California, United States +39 more locations

Tempus Priority Study: A Pan-tumor Observational Study

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Pancreatic Cancer Trials in Other Cities

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Pancreatic Cancer & Surgical Resection

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Milademetan in Advanced/Metastatic Solid Tumors

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Other Conditions in Dallas